• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Korro Bio Inc.

    6/16/26 4:42:59 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KRRO alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001997992
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Korro Bio, Inc.
    SEC File Number
    001-39062
    Address of Issuer
    60 FIRST STREET
    2ND FLOOR, SUITE 250
    CAMBRIDGE
    MASSACHUSETTS
    02141
    Phone
    617-468-1999
    Name of Person for Whose Account the Securities are To Be Sold
    Chappell Todd
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    316834309.761442257106/16/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/15/2026Restricted Stock VestingIssuerCheckbox not checked316806/15/2026Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    06/16/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Gerardo Ibarra-Munoz, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Todd Chappell

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $KRRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KRRO

    DatePrice TargetRatingAnalyst
    5/18/2026$21.00Buy
    Citigroup
    3/13/2026$23.00Mkt Perform → Outperform
    Raymond James
    2/17/2026Mkt Perform → Outperform
    William Blair
    1/29/2026$30.00Neutral → Overweight
    Piper Sandler
    1/29/2026$15.00Neutral → Buy
    Chardan Capital Markets
    1/29/2026$20.00Neutral → Buy
    H.C. Wainwright
    1/28/2026$21.00Neutral → Overweight
    Cantor Fitzgerald
    1/28/2026$22.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $KRRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Chappell Todd sold $34,309 worth of shares (3,168 units at $10.83), decreasing direct ownership by 16% to 16,964 units (SEC Form 4) to satisfy withholding tax

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    6/17/26 4:14:03 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Vincent Loic A sold $37,017 worth of shares (3,418 units at $10.83), decreasing direct ownership by 16% to 18,297 units (SEC Form 4) (withholding obligation)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    6/17/26 4:11:04 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Cerio Jeffrey sold $71,575 worth of shares (6,609 units at $10.83), decreasing direct ownership by 16% to 35,293 units (SEC Form 4) (tax liability)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    6/17/26 4:08:03 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    SEC Filings

    View All

    SEC Form 144 filed by Korro Bio Inc.

    144 - Korro Bio, Inc. (0001703647) (Subject)

    6/16/26 4:42:59 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Korro Bio, Inc. (0001703647) (Filer)

    5/19/26 7:00:17 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Korro Bio Inc.

    SCHEDULE 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    5/15/26 4:30:32 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Sandell Scott D bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:15 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner New Enterprise Associates 17, L.P. bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:13 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Yang Rick bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    3/12/26 8:15:16 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Korro to Present at the 2026 Jefferies Global Healthcare Conference

    CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 2026 Jefferies Global Healthcare Conference being held in New York, NY on June 2nd- 4th, 2026. Dr. Aiyar's presentation will take place on Thursday, June 4, 2026, at 4:20 pm ET. About Korro Korro is a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a ne

    5/27/26 7:00:00 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

    Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungsDemonstrated >90% editing of SERPINA1 transcript in vivo translating into ~90% repaired functional alpha-1 antitrypsin (AAT) protein in plasma in a mouse model of AATDDemonstrated a near elimination of active Z-protein production while showing progressive clearance of pre-existing aggregates in a mouse model of AATDPre-clinical data highlighted the possibility of repeat dose therapy to achieve the functional equivalent of a DNA modification without altering the genome CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Korro

    5/19/26 7:00:00 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee. Korro granted the new employee a nonstatutory stock option to purchase 3,000 shares of Korro's common stock at an exercise price of $11.20 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, May 13, 2026. The option has a ten-year term and vests over four years, with 2

    5/15/26 4:05:00 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Korro Bio with a new price target

    Citigroup initiated coverage of Korro Bio with a rating of Buy and set a new price target of $21.00

    5/18/26 8:34:22 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Bio upgraded by Raymond James with a new price target

    Raymond James upgraded Korro Bio from Mkt Perform to Outperform and set a new price target of $23.00

    3/13/26 8:41:33 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Bio upgraded by William Blair

    William Blair upgraded Korro Bio from Mkt Perform to Outperform

    2/17/26 7:51:08 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 7:54:42 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 3:04:22 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 12:21:08 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Leadership Updates

    Live Leadership Updates

    View All

    Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

    CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

    4/1/25 7:30:00 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

    CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

    12/10/24 8:00:00 AM ET
    $CAMP
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

    - Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko

    11/12/24 4:05:00 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care